A next-generation Biotechnology company creating off-the-shelf cellular medicines for Cancer, Infectious Diseases, and Degenerative Diseases. (NASDAQ:CELU)
170 Park Ave, Florham Park NJ
- Tweets 282
- Following 257
- Followers 7,172
- Likes 6
RELEASE: Celularity is proud to announce a U.S. manufacturing collaboration with MuseCell Innovations® to support the Dezawa MuseCell® platform at our Florham Park, New Jersey facility. businesswire.com/news/home/2… #CellularMedicine #Biomanufacturing #MuseCells
1
2
4
344
RELEASE: Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law
Read the full release here:
globenewswire.com/news-relea…
1
1
3
216
RELEASE: Celularity secures strategic license deal worth up to $35M, strengthening capital position while focusing on longevity therapeutics.
Read the full release here:
globenewswire.com/news-relea…
1
4
333
RELEASE: Celularity Inc. (Nasdaq: CELU) Receives $12.2 Million from Sale of New Jersey Net Operating Losses
Read the full release here: globenewswire.com/news-relea…
1
2
322
RELEASE: Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations
Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz.
globenewswire.com/news-relea…
4
5
475
RELEASE: Celularity announces the closing of its previously disclosed financing transactions with Philip A. Barach, co-founder and former president of DoubleLine Capital LP.
globenewswire.com/news-relea…
2
209
RELEASE: Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision
READ THE FULL RELEASE HERE:
globenewswire.com/news-relea…
161
Big announcement! We are excited to be part of DefEYE’s focused expansion into the ophthalmic space and to demonstrate the transformative power of placental-derived regenerative biologic solutions.
Read the full release here: globenewswire.com/news-relea…
5
8
653
Exciting news! Celularity Phase 2 clinical trial results published on the safety and efficacy of placenta-derived cells for diabetic foot ulcers complicated by Peripheral Artery Disease.
Read the full release here: globenewswire.com/news-relea…
1
2
6
630
We are pleased to report that we have filed our Form 10-Q quarterly reports for the first and the second quarters 2025. This comes on the heels of the recently announced retirement of all $32.0 million senior secured debt.
Read the full release here:
globenewswire.com/news-relea…
1
2
5
565
We have successfully monetized Celularity’s intellectual property assets to retire the Company’s senior secured debt in its entirety while retaining exclusive use of the assets for our cell therapy, advanced biomaterials, and biobanking businesses.
globenewswire.com/news-relea…
1
5
14
1,018
RELEASE: Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law
Read it here:
globenewswire.com/news-relea…
1
7
15
1,134
Release: Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies
globenewswire.com/news-relea…
2
2
11
1,094
Advancing Ocular Surface Reconstruction: Our DDHAM-3L technology, with its unique biological properties, offers a promising platform for delivering patient-specific, iPSC-derived LSCs to restore vision and improve patient outcomes. globenewswire.com/news-relea…
1
3
6
661
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
Read the full release here: globenewswire.com/news-relea…
1
4
9
853
An important publication form our team in Frontiers in Immunology: Senescence, NK Cells, and Cancer.
Read the full release - with link to the publication - here:
globenewswire.com/news-relea…
1
4
589
Excited to receive FDA Tissue Reference Group recommendation letters on the newest additions to our portfolio of human placental-derived biomaterials. Full story here: globenewswire.com/news-relea…
1
5
612
We are delighted to announce a strategic collaboration with BlueSphere Bio, Inc., which will bring together our core strengths in cell manufacturing, process development and BSB’s development of novel cell therapies to treat high risk leukemias. globenewswire.com/news-relea…
1
5
621
Celularity Founder and CEO Dr. Robert Hariri to be a Keynote Speaker at the Longevity Med Summit this May, discussing cellular therapies for human performance and longevity.
#longevity #stemcells
lifespan.io/news/the-3rd-lon…
2
13
685
A great feature in Drug Target Review's Beyond the Lab Report on the work Celularity is doing in the realm of stem cell therapies. (Found on page 6.)
indd.adobe.com/view/d551a70e…
2
10
1,108